Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange regarding 'Allotment of ESOPs'. The company has approved the allotment of 900 Equity Shares under the OneSource Specialty Pharma Limited – Employee Stock Option Plan 2021 to eligible employees upon exercise of vested options. The paid-up share capital of the Company has increased from INR. 11,46,72,891/- to INR. 11,46,73,791/-.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has closed its trading window from October 1, 2026, until 48 hours after the declaration of its financial results for the quarter ended September 30, 2026.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has submitted the Exchange a copy Scrutinizer's report and voting results for the 19th AGM held on September 23, 2026, where 7 resolutions were passed with 100% approval from promoters and public shareholders, including the re-appointment of Neeraj Sharma as Director and appointment of Statutory Auditors.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange regarding the appointment of new statutory auditors, M/s B S R & Co LLP, for a period of 5 years from the conclusion of the 19th Annual General Meeting.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited held its 19th Annual General Meeting (AGM) on September 23, 2026, through video conference. The meeting was attended by 81 shareholders holding 3,46,04,605 shares. The company's CEO, Neeraj Sharma, briefed the shareholders on the company's performance for the financial year ended March 31, 2026, and provided key strategic updates.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange regarding 'Addendum to the notice of the 19th AGM scheduled to be held on September 23, 2026. The addendum includes additional disclosures regarding material related party transactions with Strides Pharma Science Limited and Strides Pharma Inc, USA.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about Investor Presentation, which can be accessed on their website.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about the dispatch of Notice of the 19th Annual General Meeting (AGM) and Remote e-voting.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has submitted its Business Responsibility & Sustainability Report (BRSR) for FY26, as required by SEBI regulations.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026. The company has also enclosed the Notice of the 19th AGM and the Integrated Annual Report for the financial year 2025-26.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about a scheduled analyst/institutional investor meet on September 03, 2026, at their manufacturing facility in Doddaballapura, Bengaluru Rural District.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the 19th AGM of the Company.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about Credit Rating upgrade by India Ratings & Research (Ind-Ra) for its bank loan facilities.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has informed the Exchange about Earnings Call Transcript dated July 25, 2026. The company's CEO and MD, Neeraj Sharma, and CFO, Anurag Bhania, presented the key business and financial highlights for the quarter ended June 30, 2026. Revenues grew 37% year-on-year to INR4,490 million, driven by the semaglutide commercial launch, new MSA contracts, and new customer wins. EBITDA increased 39% year-on-year to INR1,233 million, with a sequential quarter-on-quarter growth of 34%. The company has made significant progress in its sema commercialization in Canada and has launched new products in India.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has announced a change in management, with Preeti Kalra being designated as a Senior Management Personnel (SMP) and Ravi Kumar resigning as Global Head – Injectables/ Head of Corporate Strategy, Portfolio & SPO, effective July 24, 2026.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has published un-audited financial results for the quarter ended June 30, 2026, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited has informed the Exchange about the link of the recording of their earnings call for the unaudited financial results for the quarter ended June 30, 2026. The recording is available on their website.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange regarding the allotment of 2,900 Equity Shares under the OneSource Specialty Pharma Limited – Employee Stock Option Plan 2021 to eligible employees upon exercise of vested options. The paid-up share capital of the Company has increased from INR. 11,46,69,991/- to INR. 11,46,72,891/-.

Onesource Specialty Pharma Limited

OneSource Specialty Pharma Limited announced its Q1FY27 results with revenue up 37% YoY and EBITDA up 39% YoY, driven by commercialisation of semaglutide in Canada and India. The company reaffirmed its FY28 guidance of $400 million in organic revenue with 40% EBITDA margin.

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited has informed the Exchange about change in Management of the Company, with Preeti Kalra being designated as a Senior Management Personnel and Ravi Kumar resigning from his position.